A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer
CONCLUSION: This study could not demonstrate that adding Bev to ddTC improves prognosis. Further studies with more cases are warranted.PMID:38576344 | DOI:10.3802/jgo.2024.35.e76 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Hiromi Komazaki Kazuaki Takahashi Hiroshi Tanabe Yuichi Shoburu Misato Kamii Akina Tsuda Motoaki Saito Kyosuke Yamada Hirokuni Takano Hirofumi Michimae Aikou Okamoto Source Type: research
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
CONCLUSION: At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.PMID:38576343 | DOI:10.3802/jgo.2024.35.e71 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - April 5, 2024 Category: OBGYN Authors: Youwen Zhu Yinxin Lin Kun Liu Hong Zhu Source Type: research
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
ConclusionsNeither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy.Clinical trial registryClinicalTrials.gov Identifier: NCT01733628. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 5, 2024 Category: Cancer & Oncology Source Type: research
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Conclusion: In this study, the RWD ECA was unable to successfully replicate the OS estimates from the matched population of the selected RCT. The inability to replicate could be due to unmeasured confounding and variations in time-periods, follow-up and subsequent therapy. Despite these findings, we demonstrate how BB can improve precision of comparative effectiveness estimates, potentially aid as a bias assessment tool and mitigate challenges of traditional methods when appropriate external data sources are available.PMID:38573331 | DOI:10.57264/cer-2023-0175 (Source: Cell Research)
Source: Cell Research - April 4, 2024 Category: Cytology Authors: Alessandria Struebing Chelsea McKibbon Haoyao Ruan Emma Mackay Natalie Dennis Russanthy Velummailum Philip He Yoko Tanaka Yan Xiong Aaron Springford Mats Rosenlund Source Type: research
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Conclusion: In this study, the RWD ECA was unable to successfully replicate the OS estimates from the matched population of the selected RCT. The inability to replicate could be due to unmeasured confounding and variations in time-periods, follow-up and subsequent therapy. Despite these findings, we demonstrate how BB can improve precision of comparative effectiveness estimates, potentially aid as a bias assessment tool and mitigate challenges of traditional methods when appropriate external data sources are available.PMID:38573331 | DOI:10.57264/cer-2023-0175 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - April 4, 2024 Category: General Medicine Authors: Alessandria Struebing Chelsea McKibbon Haoyao Ruan Emma Mackay Natalie Dennis Russanthy Velummailum Philip He Yoko Tanaka Yan Xiong Aaron Springford Mats Rosenlund Source Type: research
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
CONCLUSION: For patients with EGFR20ins mutation, compared to chemotherapy, ICI+Chemo prolongs PFS, and after chemotherapy progression, bevacizumab combined with chemotherapy seems better than Furmonertinib-based targeted therapy on PFS. For HER2-20ins mutation, Beva+Chemo may be a better choice.PMID:38567147 | PMC:PMC10985835 | DOI:10.3389/fonc.2024.1357231 (Source: Cancer Control)
Source: Cancer Control - April 3, 2024 Category: Cancer & Oncology Authors: Jiaqi Li Mengqing Xie Ruiying Zhao Huiping Qiang Qing Chang Jialin Qian Haijiao Lu Yinchen Shen Yuchen Han Chunxia Su Tianqing Chu Source Type: research
LC –MS Characterization and Stability Assessment Elucidate Correlation Between Charge Variant Composition and Degradation of Monoclonal Antibody Therapeutics
In this study, correlation between charge heterogeneity and stability of mAbs for bevacizumab and trastuzumab has been investigated under a variety of stresses including thermal stress at 40 °C, thermal stress at 55 °C, shaking (mechanical), and low pH. Size- and charge-based heterogeneities were monitored using analytical size exclusion chromatography (SEC) and cation exchange chromatography (CEX), respectively, while dynamic light scattering was used to assess changes in hydrod ynamic size. CEX analysis revealed an increase in cumulative acidic content for all variants of both mAbs post-stress treatment attributed...
Source: The AAPS Journal - April 3, 2024 Category: Drugs & Pharmacology Source Type: research
Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm < sup > 3 < /sup > : a multi-center study
Neurosurg Rev. 2024 Apr 2;47(1):137. doi: 10.1007/s10143-024-02369-1.ABSTRACTDespite 2-staged stereotactic radiosurgery (2-SSRS) has been reported to provide patients with improved survival and limited toxicity, 2-SSRS for brainstem metastases (BSM) larger than 2 cm3 remains challenging. We tried to find out the effectiveness and safety of 2-SSRS plus bevacizumab therapy for BSMs over 2 cm3 and prognostic factors that related to the tumor local control. Patients that received 2-SSRS plus bevacizumab therapy from four gamma knife center were retrospectively studied from Jan 2014 to December 2023. Patients' domestic characte...
Source: Cancer Control - April 2, 2024 Category: Cancer & Oncology Authors: Zheng Wang Haining Chen Qun Chen Yucun Zhu Min Li Jia Zhou Lingfei Shi Source Type: research
Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review
CONCLUSION: Atezolizumab/bevacizumab treatment might exacerbate portal hypertension. Careful monitoring and management should be considered during treatment.PMID:38565487 | DOI:10.1016/j.jfma.2024.03.019 (Source: Cancer Control)
Source: Cancer Control - April 2, 2024 Category: Cancer & Oncology Authors: Tung-Yen Lin Tung-Hung Su Source Type: research
